Tag: solution

SCOTTSDALE, Ariz., June 16, 2025 (GLOBE NEWSWIRE) -- BlueGenes, a leading pharmacogenetics (PGX) solution, and Levrx Technology, a digital pharmacy engagement platform, have announced a strategic partnership. Together they aim to accelerate the adoption of personalized prescribing by seamlessly integrating genetic testing insights into pharmacy benefit systems.

Strategic federal initiative includes appointment of Jason Chasse, a US Federal and Military sales veteran with over 30 years of experience, as Director of Federal Sales.

Ningbo, China, June 16, 2025 (GLOBE NEWSWIRE) -- Skycorp Solar Group Limited (the “Company”) (NASDAQ: PN), a solar PV product provider engaged in the manufacture and sale of solar cables and solar connectors, highlighted its latest innovations at the 18th SNEC International Photovoltaic Power Generation and Smart Energy Conference & Exhibition. From June 11-13, 2025, its subsidiary, Ningbo Pntech New Energy Co., Ltd. (“PNTECH”), introduced advanced photovoltaic connection solutions, drawing substantial industry attention and reinforcing its position in renewable energy cable development.

FREMONT, Calif., June 16, 2025 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today announced the launch of its most powerful and versatile battery yet, the IQ^® Battery 5P™ with FlexPhase, for customers in Spain, Portugal, France, Sweden, Denmark, Belgium, and the Netherlands. The IQ Battery 5P with FlexPhase is an all-in-one AC-coupled system that delivers reliable backup power and supports both single-phase and three-phase applications, providing unmatched flexibility to meet diverse home energy needs. Enphase also launched the IQ Battery 5P with FlexPhase in Poland, Luxembourg, Germany, Austria, and Switzerland earlier this year.

MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory trial of OCU410ST, a modifier gene therapy candidate being developed for all Stargardt disease (ABCA4-associated retinopathies). The FDA previously granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.